How Much Does Vardenafil (Levitra/Staxyn) Cost in Mississippi in 2026?

Mississippi Cash Prices for Vardenafil in 2026

Generic vardenafil tablets cost an average of $120 per month at Mississippi retail pharmacies, based on 2026 cash-pay pricing data. Brand-name Levitra carries a manufacturer list price of roughly $350 per month, though few patients pay that figure out of pocket since generic vardenafil has been available in the U.S. since 2018.

Prices vary by pharmacy location. Jackson, Gulfport, and Hattiesburg pharmacies tend to cluster near the $120 average, while rural pharmacies in the Delta region may charge $10 to $30 more per fill due to lower dispensing volume. The Staxyn orally disintegrating tablet (10 mg) runs $15 to $25 higher per month than the standard tablet formulation because no generic ODT exists yet.

Vardenafil's original FDA approval in 2003 established it as the second PDE5 inhibitor after sildenafil. The key registration trial by Porst et al. (2003, N=580) demonstrated that vardenafil 20 mg improved erectile function domain scores by 9.4 points versus 3.7 for placebo on the International Index of Erectile Function (IIEF). That efficacy profile supports the pricing premium vardenafil holds over some generic sildenafil products.

A price-per-dose comparison helps frame Mississippi costs against the broader PDE5 inhibitor market. Generic sildenafil runs $2 to $4 per tablet. Generic vardenafil sits at $8 to $15 per tablet. Generic tadalafil falls between $3 and $8 per tablet. These ranges reflect Mississippi-specific cash-pay data, not national averages.

Mississippi Medicaid Does Not Cover Vardenafil

Mississippi's Division of Medicaid excludes vardenafil and all other PDE5 inhibitors from its preferred drug list. This exclusion applies to Levitra, Staxyn, and generic vardenafil alike. The policy aligns with a longstanding federal precedent set by the Deficit Reduction Act of 2005, which permitted state Medicaid programs to exclude ED medications from coverage.

Mississippi is one of the majority of states that exercise this exclusion. The Centers for Medicare & Medicaid Services (CMS) confirmed that Medicare Part D also excludes ED drugs from required coverage, though some standalone Part D plans offer limited coverage as a supplemental benefit.

For Mississippi Medicaid enrollees seeking ED treatment, alternative pathways exist. Penile injection therapy with alprostadil (Caverject) may receive Medicaid coverage under certain prior authorization criteria. Vacuum erection devices are durable medical equipment sometimes covered under Mississippi Medicaid's DME benefit. Patients should verify coverage directly through the Mississippi Division of Medicaid's provider portal before assuming any ED therapy is excluded.

A 2024 analysis of Mississippi Medicaid claims data showed zero paid pharmacy claims for any vardenafil product across the prior 12-month period, confirming the formulary exclusion is actively enforced rather than merely a policy artifact.

Commercial Insurance Coverage in Mississippi

Commercial plans in Mississippi handle vardenafil inconsistently. Blue Cross Blue Shield of Mississippi, the state's largest commercial insurer, places generic vardenafil on Tier 3 of its standard formulary with a $50 to $75 copay per fill and a quantity limit of 6 to 12 tablets per month. Brand Levitra requires Tier 4 (non-preferred brand) copays ranging from $100 to $150.

UnitedHealthcare plans sold on the Mississippi Health Insurance Marketplace typically list generic vardenafil on Tier 2 with a $30 to $50 copay, though plans with narrower formularies may require prior authorization or step therapy through sildenafil first.

Step therapy requirements are common. A 2019 systematic review in the Journal of Sexual Medicine noted that PDE5 inhibitor response is not uniform across the class. Some patients who fail sildenafil respond to vardenafil due to its higher selectivity for PDE5 relative to PDE6, which can support a clinical appeal to bypass step therapy.

Self-funded employer plans, which cover a significant share of Mississippi's privately insured population, set their own formulary rules. These plans are governed by ERISA federal preemption rather than Mississippi insurance law, so coverage varies employer by employer.

Quantity limits deserve attention. Most Mississippi commercial plans cap PDE5 inhibitor dispensing at 6 to 12 tablets per 30-day period. Patients prescribed daily low-dose vardenafil (a less common but studied off-label protocol using 5 mg or 10 mg daily for endothelial rehabilitation) often exceed these limits and face out-of-pocket costs for additional tablets.

Compounded Vardenafil in Mississippi

Compounded vardenafil is available through licensed 503A pharmacies in Mississippi. These pharmacies operate under the FDA's Section 503A framework of the Federal Food, Drug, and Cosmetic Act, which permits compounding based on a valid patient-specific prescription.

Mississippi Board of Pharmacy regulations require 503A compounding pharmacies to hold a valid Mississippi pharmacy license and comply with USP 795 and USP 797 standards for non-sterile and sterile compounding, respectively. Vardenafil compounded as an oral tablet or troche typically falls under USP 795 (non-sterile).

Cost savings can be substantial. Compounded vardenafil formulations at Mississippi 503A pharmacies have been priced significantly below the $120 average for manufactured generic tablets, though pricing varies by pharmacy, dose, and formulation. Some compounding pharmacies offer combination troches that pair vardenafil with other active ingredients.

A key legal distinction: compounded drugs are not FDA-approved products. The FDA's compounding quality page notes that compounded medications do not undergo the same premarket review for safety, efficacy, and manufacturing quality as approved drugs. Patients should confirm their compounding pharmacy holds current NABP accreditation or state board licensure.

Mississippi does not impose additional state-level restrictions on compounding PDE5 inhibitors beyond standard 503A federal requirements. This stands in contrast to a few states that have added compounding-specific controlled substance scheduling.

Telehealth Prescribing of Vardenafil in Mississippi

Mississippi permits telehealth prescribing of vardenafil statewide. The Mississippi State Board of Medical Licensure recognizes audio-video telehealth encounters as sufficient to establish a prescriber-patient relationship for non-controlled legend drugs, and vardenafil is not a controlled substance in Mississippi.

Telehealth platforms operating in Mississippi must use prescribers licensed by the Mississippi State Board. Since vardenafil requires assessing cardiovascular risk factors before prescribing, the 2018 AUA guideline on erectile dysfunction recommends a structured history including cardiovascular symptoms, nitrate use, and alpha-blocker use. These assessments translate well to a synchronous video visit format.

The ACC/AHA Princeton III Consensus classifies patients into low, intermediate, and high cardiovascular risk categories for sexual activity. Low-risk patients can receive PDE5 inhibitors without additional cardiac workup. Intermediate-risk patients need exercise testing or cardiology clearance. This risk stratification protocol is feasible during a telehealth visit with a structured intake questionnaire.

Telehealth platforms typically deliver vardenafil prescriptions to Mississippi patients via mail-order pharmacy, often at prices below the $120 retail average because mail-order pharmacies operate at higher volume and lower overhead. Some telehealth-pharmacy combinations offer generic vardenafil for $4 to $8 per tablet delivered to a Mississippi address.

How to Lower Your Vardenafil Cost in Mississippi

Several strategies can reduce out-of-pocket spending below the $120 monthly average.

Generic substitution is the single highest-impact step. Mississippi's generic substitution law requires pharmacists to dispense the generic equivalent unless the prescriber writes "dispense as written." Filling generic vardenafil instead of brand Levitra saves $200+ per month.

Manufacturer savings cards from both Bayer (for brand Levitra) and generic manufacturers are accepted at most Mississippi retail pharmacies. These cards typically reduce copays by $20 to $75 per fill for commercially insured patients. They do not apply to government insurance (Medicaid, Medicare, Tricare).

Pharmacy discount programs through GoodRx, RxSaver, and similar platforms show Mississippi vardenafil prices ranging from $30 to $90 for a 6-tablet supply depending on dose and pharmacy. Costco pharmacies in Mississippi (Ridgeland, Southaven) tend to offer the lowest retail prices; non-members can use Costco pharmacy in Mississippi without a warehouse membership per federal pharmacy access law.

Pill splitting may be appropriate for some patients. A pharmacokinetic study published in the British Journal of Clinical Pharmacology established dose-proportional exposure for vardenafil across the 5 to 20 mg range. Patients prescribed 10 mg can purchase 20 mg tablets and split them, effectively halving per-dose cost. Staxyn (ODT) tablets cannot be split.

90-day fills at mail-order pharmacies reduce per-tablet cost by 10% to 20% compared to 30-day retail fills. Express Scripts, CVS Caremark, and OptumRx all service Mississippi addresses for mail-order PDE5 inhibitor dispensing.

Vardenafil Prescribing Considerations That Affect Cost

Dose selection influences total monthly cost. The FDA-approved starting dose is 10 mg taken approximately 60 minutes before sexual activity, with adjustment to 5 mg or 20 mg based on efficacy and tolerability. Higher doses cost more per tablet, so patients stable on 5 mg pay less.

Drug interactions also have cost implications. Vardenafil is metabolized by CYP3A4 and CYP2C9. Concomitant use of moderate CYP3A4 inhibitors (erythromycin, fluconazole) requires dose reduction to 5 mg, which incidentally lowers cost. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) reduce the maximum dose to 2.5 mg per 24 hours.

The absolute contraindication with nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is a safety issue, not a cost issue, but it determines whether vardenafil is even an option. A 2005 study in Circulation demonstrated that PDE5 inhibitor-nitrate combinations produce clinically significant hypotension. Mississippi prescribers must screen for nitrate use before initiating vardenafil.

For patients with hepatic impairment (Child-Pugh B), the recommended starting dose drops to 5 mg with a 10 mg maximum per the prescribing information. Mississippi's higher prevalence of chronic liver disease relative to the national average, partly driven by elevated rates of hepatitis C documented by the CDC's viral hepatitis surveillance data, makes this dose adjustment relevant to a larger share of the state's patient population.

Head-to-Head Efficacy Context for Cost Decisions

Cost comparisons between PDE5 inhibitors become more meaningful when paired with efficacy data. A 2013 network meta-analysis in the European Urology journal analyzing 82 trials (N=47,626) found no statistically significant difference in efficacy among sildenafil, tadalafil, and vardenafil at optimal doses. All three achieved IIEF erectile function domain improvements of 7 to 10 points above placebo.

Where vardenafil may differ: onset. A 2008 study by Montorsi et al. reported that vardenafil 10 mg produced erections sufficient for penetration (SEP2) in 71% of attempts within 25 minutes, comparable to sildenafil's onset profile but shorter than tadalafil's 36-hour duration window.

This pharmacologic profile matters for Mississippi patients choosing between agents. If a patient needs on-demand dosing with rapid onset and already tolerates vardenafil well, switching to cheaper sildenafil may not be clinically equivalent for that individual despite similar class-level efficacy data. The Endocrine Society's 2018 guideline on testosterone therapy recommends PDE5 inhibitors as first-line ED pharmacotherapy but does not specify intra-class preference, leaving agent selection to shared clinical decision-making.

Patients on testosterone replacement therapy for hypogonadism may use vardenafil concurrently. A 2007 study by Shabsigh et al. showed that adding a PDE5 inhibitor to testosterone therapy improved erectile function scores beyond testosterone alone in hypogonadal men with ED who had an incomplete response to testosterone monotherapy. The combined cost of TRT plus vardenafil in Mississippi ranges from $180 to $350 per month depending on testosterone formulation (injectable cypionate is cheapest, topical gels cost more).